Runwal Pranav, Pyun Jae, Newman Stephanie A, Mawal Celeste, Bush Ashley I, Koehn Liam M, Nicolazzo Joseph A
Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Oxidation Biology Lab, Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia.
Pharm Res. 2025 Feb;42(2):319-334. doi: 10.1007/s11095-025-03826-2. Epub 2025 Feb 12.
Iron overload is implicated in many neurodegenerative diseases, where there is also blood-brain barrier (BBB) dysfunction. As there is a growing interest in the role of iron in modulating key BBB proteins, this study assessed the effect of iron on the expression and function of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and claudin-5 in primary mouse brain endothelial cells (MBECs) and their abundance in mouse brain microvessel-enriched membrane fractions (MVEFs).
Following a 48 h treatment with ferric ammonium citrate (FAC, 250 µM), MBEC protein abundance (P-gp, BCRP and claudin-5) and mRNA (abcb1a, abcg2, and cldn5) were assessed by western blotting and RT-qPCR, respectively. Protein function was evaluated by assessing transport of substrates H-digoxin (P-gp), H-prazosin (BCRP) and C-sucrose (paracellular permeability). C57BL/6 mice received iron dextran (100 mg/kg, intraperitoneally) over 4 weeks, and MVEF protein abundance and iron levels (in MVEFs and plasma) were quantified via western blotting and inductively coupled plasma-mass spectrometry (ICP-MS), respectively.
FAC treatment reduced P-gp protein by 50% and abcb1a mRNA by 43%, without affecting H-digoxin transport. FAC did not alter BCRP protein or function, but decreased abcg2 mRNA by 59%. FAC reduced claudin-5 protein and cldn5 mRNA by 65% and 70%, respectively, resulting in a 200% increase in C-sucrose permeability. In vivo, iron dextran treatment significantly elevated plasma iron levels (2.2-fold) but did not affect brain MVEF iron content or alter P-gp, BCRP or claudin-5 protein abundance.
Iron overload modulates BBB transporters and junction proteins in vitro, highlighting potential implications for CNS drug delivery in neurodegenerative diseases.
铁过载与许多神经退行性疾病有关,这些疾病中还存在血脑屏障(BBB)功能障碍。由于人们对铁在调节关键血脑屏障蛋白中的作用越来越感兴趣,本研究评估了铁对原代小鼠脑内皮细胞(MBECs)中P-糖蛋白(P-gp)、乳腺癌耐药蛋白(BCRP)和紧密连接蛋白-5的表达和功能的影响,以及它们在小鼠脑微血管富集膜组分(MVEFs)中的丰度。
用柠檬酸铁铵(FAC,250μM)处理48小时后,分别通过蛋白质印迹法和RT-qPCR评估MBEC蛋白丰度(P-gp、BCRP和紧密连接蛋白-5)和mRNA(abcb1a、abcg2和cldn5)。通过评估底物H-地高辛(P-gp)、H-哌唑嗪(BCRP)和C-蔗糖(细胞旁通透性)的转运来评估蛋白质功能。C57BL/6小鼠在4周内接受右旋糖酐铁(100mg/kg,腹腔注射),并分别通过蛋白质印迹法和电感耦合等离子体质谱法(ICP-MS)对MVEF蛋白丰度和铁水平(在MVEFs和血浆中)进行定量。
FAC处理使P-gp蛋白减少50%,abcb1a mRNA减少43%,但不影响H-地高辛转运。FAC未改变BCRP蛋白或功能,但使abcg2 mRNA减少59%。FAC使紧密连接蛋白-5蛋白和cldn5 mRNA分别减少65%和70%,导致C-蔗糖通透性增加200%。在体内,右旋糖酐铁处理显著提高了血浆铁水平(2.2倍),但不影响脑MVEF铁含量,也不改变P-gp、BCRP或紧密连接蛋白-5蛋白丰度。
铁过载在体外调节血脑屏障转运蛋白和连接蛋白,突出了其对神经退行性疾病中中枢神经系统药物递送的潜在影响。